First, we evaluated the efficacy of single-agent activity of tiplaxtinin, a selective small molecule inhibitor of PAI1 [36], on breast cancer cells cultured in the presence of fibroblast-conditioned medium. This evidence concerns the gene SERPINE1 and breast cancer.